US FDA Sees Slow But Steady Progress In Adoption Of Continuous Manufacturing
Executive Summary
The COVID-19 pandemic has prompted the ICH to delay by six months its efforts to develop Q13 guideline on continuous manufacturing, now not expected until May 2022.